Darmiyan

Executive Summary

Darmiyan is a San Francisco-based neuroscience diagnostics company founded in 2015 that has developed a novel technology to assess brain health by focusing on the extracellular space between brain cells. The company's name, meaning 'in-between' in Persian, reflects its unique approach to grading the health of the brain's interstitial space, which serves as an early indicator of neurodegenerative disease. By quantifying subtle changes in this microenvironment, Darmiyan aims to identify patients in the grey zone between normal cognitive aging and pathological decline, enabling earlier intervention and monitoring of disease progression. The technology holds promise for improving diagnosis of conditions such as Alzheimer's, Parkinson's, and other dementias, where current diagnostic methods often detect disease only after significant neural damage has occurred. The company's diagnostics platform addresses a critical unmet need for non-invasive, objective biomarkers that can detect neurodegenerative changes years before clinical symptoms appear. With the global burden of dementia expected to rise, Darmiyan's approach could transform screening and monitoring paradigms, potentially reducing healthcare costs and improving patient outcomes. While the company remains privately held with limited public financial or pipeline data, its focus on an underexplored biological compartment and early-stage development position it as an intriguing player in the precision neurology space. Successful validation and regulatory clearance could position Darmiyan as a key enabler of preventative neurology and a valuable partner for pharmaceutical companies developing disease-modifying therapies.

Upcoming Catalysts (preview)

• Q3 2026Pivotal clinical study results for brain health diagnostic test70% success
• Q1 2027FDA breakthrough device designation or de novo classification60% success
• FY 2026Strategic partnership with a major pharmaceutical company for co-development50% success